Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723899 | 0.91 | MAOB (0.62) | CYP19A1ALDH1A1MAPTABCG2CYP3A4 | |
| SCHEMBL773767 | 0.90 | CYP19A1 (0.66) | CYP19A1ALDH1A1TAS2R31MAPTTDP1 | |
| SCHEMBL3368230 | 0.90 | CYP19A1 (0.59) | CYP19A1ALDH1A1TAS2R31MAPTTDP1 | |
| SCHEMBL2879029 | 0.89 | ABCG2 (0.67) | CYP19A1ALDH1A1MAPTABCG2CYP3A4 | |
| SCHEMBL5084282 | 0.82 | ABCG2 (0.68) | CYP19A1ALDH1A1TAS2R31MAPTTDP1 | |
| SCHEMBL3364494 | 0.82 | MEN1 (0.65) | CYP19A1ALDH1A1MAPTABCG2CYP3A4 | |
| SCHEMBL5085603 | 0.81 | CYP19A1 (0.82) | CYP19A1ALDH1A1TAS2R31MAPTTDP1 | |
| SCHEMBL6503931 | 0.80 | POLB (0.62) | CYP19A1ALDH1A1MAPTATMABCG2 | |
| SCHEMBL14829728 | 0.80 | CYP19A1 (0.65) | CYP19A1ALDH1A1TAS2R31MAPTATM | |
| SCHEMBL17318042 | 0.79 | CYP1A1 (0.67) | CYP19A1ALDH1A1TAS2R31MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CYP19A1 214/4885ALDH1A1 2000/4885TAS2R31 2646/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | CYP19A1 460/4885ALDH1A1 2440/4885TAS2R31 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.